Last reviewed · How we verify

NCT06926387

Bioequivalence Study betweenYHP2407 and YHR2502 in Healthy Subjects

Completed Phase 1 Last updated 13 May 2025
What this trial tests

Phase 1 trial testing YHP2407 in Healthy Volunteer in 43 participants. Completed in 29 April 2025.

Timeline
17 April 2025
Primary endpoint
19 April 2025
29 April 2025

Quick facts

Lead sponsorYuhan Corporation
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment43
Start date17 April 2025
Primary completion19 April 2025
Estimated completion29 April 2025
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Yuhan Corporation — full company profile →

Who can join

Adults 19 to 64, any sex, with Healthy Volunteer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized, open-label, single-dose, 2-sequence, 2-period, crossover clinical trial to investigate the bioequivalence between YHP2407 and YHR2502 in healthy volunteers

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy Volunteer

Currently open trials in the same condition.

Other Yuhan Corporation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06926387.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing